Virax Biolabs Group Ltd(VRAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -16.91 | Insider Own | 0.37% | Shs Outstand | 1.3M | Perf Week | -43.42% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.3M | Perf Month | -59.53% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 1.98% | Short Float | 0.5% | Perf Quarter | -76.65% |
| Income | -0.01B | P/S | 89.44 | EPS this Y | - | Inst Trans | 4.66% | Short Ratio | 0.01 | Perf Half Y | -80.92% |
| Sales | 0.00B | P/B | 0.05 | EPS next 5Y | - | ROA | -68.11% | Short Interest | 0.01M | Perf YTD | -92.28% |
| Book/sh | 13.08 | P/C | 0.14 | EPS past 3/5Y | 53.83% 2.45% | ROE | -75.7% | 52W High | -96.93% ($21.75) | Perf Year | -94.21% |
| Cash/sh | 4.81 | P/FCF | - | Sales past 3/5Y | 13.21% -36.86% | ROIC | -63.74% | 52W Low | 32.69% ($0.50) | Perf 3Y | -98.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 58.99% | Gross Margin | -3472.01% | Volatility(W/M) | 31.88% 18.74% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -537.56 | Sales Y/Y TTM | 96.22% | Oper. Margin | -51515.17% | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.97 | EPS Q/Q | 75.64% | Profit Margin | -40439.1% | RSI (14) | 23.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.97 | Sales Q/Q | 684.83% | SMA20 | -39.59% ($1.11) | Beta | 1.52 | Target Price | $25 |
| Payout | - | Debt/Eq | 0.05 | Earnings | - | SMA50 | -63.53% ($1.84) | Rel Volume | 0.13 | Prev Close | $0.63 |
| Employees | 26 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | -81.61% ($3.64) | Avg Volume(3M) | 0.63M | Price | $0.67 |
| IPO | 2022/7/21 | Option/Short | No/Yes | Trades | 294 | Volume | 84,715 | Change | 6.47% |
(Birax Biolabs) is an in-vitro diagnostics (IVD) company headquartered in Lancashire, UK. Under the ViraxClear brand, it supplies a wide range of human diagnostic kits covering respiratory, pregnancy, infectious disease, STI, drug abuse, oncology, cardiac, and women's health, while under the ViraxVet brand it provides rapid and molecular diagnostic kits for veterinary use. The company is a clinical-stage enterprise that is expanding its T-cell immunity-based viral diagnostics business.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 13% of its average volume.
VRAX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $8,944. Peers typically go for $885.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.0%.
Tap to view numbers
It ranks #591 of 597 in the industry
Based on market cap of $1M.
GOVX#589 Geovax Labs Inc $1M PER - 
MTNB#590 Matinas Biopharma Holdings Inc $1M PER - VRAX#591 Virax Biolabs Group Ltd $1M PER - 
LABT#592 Lakewood-Amedex Biotherapeutics Inc $1M PER - 
SPRC#593 SciSparc Ltd $1M PER - 
FAQ
What kind of company is VRAX?
VRAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRAX?
The market cap of VRAX is approximately $1M, ranking 5,860 within its sector.
What is the 52-week high and low for VRAX?
VRAX has recorded a 52-week high of $21.75 and a low of $0.50.
